@RichardTalbot9@DrFranckClarot@mimiryudo@FMFofficiel Désolé, mais la formulation reste « misleading », car les dénominateurs sont différents :
- oui, ~80% des cancers diagnostiqués par dépistage st vivants à 5 ans
- MAIS la mortalité globale (nb de décès à 5 ans) n’est diminuée « que » de 20% ds NLST, et 25-30% ds NELSON. Pas 80%…
@GerardAraud « Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of our passion, they cannot alter the state of facts and evidence. »
John Adams, POTUS #2
Not #45 (and elected #47…😢)
@DrEmilyMcD@RodgerMarc In Europe, about 3% of all patients with acute DVT/PE get a filter (eg, Jimenez JACC 2016, 67:162-70)
In the US, the figure is about 15% 😳(eg, Bikdeli JACC 2016, 67:1027-35)
Good news the indefensible high rate in the US is decreasing.👍
Suspected pulmonary embolism in the emergency department: over-, under- and/or mis-testing? - The Lancet Regional Health – Europe https://t.co/HraWzIq3HU
@BenjaminBesseMD Not that counterintuitive, Benjamin 😉
The ablation of all visible mets automatically impacts PFS, whereas OS is driven by many other factors, including invisible mets.
Current definition of oligometastatic is too dependent on imaging with very poor detectability of small mets.
@docisa33 Rond, pas lobe sup, et surtout très bien limité = BENIN jusqu’à preuve du contraire : tumeur benigne ou peu agressive (carcinoide?), voire épanchement inter-scissural.
Si non fumeur et pas de cancer extra thoracique connu, probabilité malignité <10% (extrapolation Herder score)
@MarcCarrier1@justine_ryu@jzbos@rushadpatell@ASH_hematology@JTHjournal Warfarin « confers » OS benefit ? Looks like an overstatement, Marc.
Remember when the opposite was suggested (OS on LMWH > VKA in the CLOT trial, Agnes Lee JCO 2005 DOI: 10.1200/JCO.2005.03.133)?
Confounding, confounding until proven otherwise.
@DrHooksDO No surprise, alas…
And not better than in…1988 !
Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med. 1988 Jun;148(6):1321-5. PMID: 3377615.
@FilippoMontemu1@CadranelJ Weak data :
1. negative trial (primary outcome= RDI)
2. pCR after neo-adj CT = secondary outcome
3. randomisation not stratified on neo-adj CT
4. pCR after neo-adj CT: 21/40 vs 9/32, p=0.037. But with only ONE change in either group, p ➡️>0.05.
Definitely "require confirmation"
@macromik 100% d’accord évidemment https://t.co/jdfHpB7P2O Message important pour certains oncologues/chirugiens/radiologues interventionnels: pas de traitement local pour les très petites métastases pulmonaires !
@AVR_MVR@kashishgoelmd @VUMC_ECMO @vumcvalve @VUMChealth Impressive. Congrats.
But also interested in clinical outcome: did the procedure help weaning from ECMO and/or ventilator ? In other words: what about microcirculation ?
The CASTA DIVA trial comparing rivaroxaban to dalteparin in CAT published in @accpchest today. Great work from @INNOVTE1
Rivaroxaban was associated with low risk of recurrent VTE and bleeding
https://t.co/sSNIN7Ld0z
@Philipp92515773@LaurentBertole1@FCouturaud
⏭️ @IFrachon dans une tribune @lemondefr critique la composition de la nouvelle cellule anti-complotisme
L'occasion d'un rappel de l'affaire #Mediator
https://t.co/nChNxmzx75